| Ticker Details |
Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.
|
| IPO Date: |
October 1, 2002 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$153.45M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.16 | 4.34%
|
| Avg Daily Range (30 D): |
$0.12 | 4.95%
|
| Avg Daily Range (90 D): |
$0.11 | 4.14%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.22M |
| Avg Daily Volume (30 D): |
.3M |
| Avg Daily Volume (90 D): |
.3M |
| Trade Size |
| Avg Trade Size (Sh.): |
248 |
| Avg Trade Size (Sh.) (30 D): |
100 |
| Avg Trade Size (Sh.) (90 D): |
110 |
| Institutional Trades |
| Total Institutional Trades: |
53 |
| Avg Institutional Trade: |
$1.96M |
| Avg Institutional Trade (30 D): |
$.57M |
| Avg Institutional Trade (90 D): |
$.57M |
| Avg Institutional Trade Volume: |
.4M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.59M |
| Avg Closing Trade (30 D): |
$.57M |
| Avg Closing Trade (90 D): |
$.57M |
| Avg Closing Volume: |
856.99K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$-.41
|
$-.08
|
$-.08
|
|
Diluted EPS
|
$-.41
|
$-.08
|
$-.08
|
|
Revenue
|
$M
|
$M
|
$M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-26.25M
|
$-5.05M
|
$-5.5M
|
|
Operating Income / Loss
|
$-16.27M
|
$-4.08M
|
$-3.37M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$7.69M
|
$M
|
$M
|
|
PE Ratio
|
|
|
|
|
|
|
